Extraordinary Resolutions
NB | Resolution | Result | For | Against | Vote withhold |
Total votes |
Shares represented by the votes cast |
Percentage of the share capital represented by the votes cast |
Out of vote voting rights |
Null voting rights | Quorum | ||||||||||||||||||||||||||||||||||||||||||||
Votes | % | Votes | % | Votes | % | ||||||||||||||||||||||||||||||||||||||||||||||||||
1 |
Creation of a class of preferred shares referred to as "Class A preferred shares" convertible into ordinary shares (the "A Shares") - determination of the specific rights attached to the A Shares - corresponding amendment to the bylaws | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 | Carried | 26 188 875 | 99,65 | % | 92 063 | 0,35 | % | 35 416 | - | 26 280 938 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
2 |
Delegation of authority to the board of directors to increase the share capital by a maximum nominal amount of EUR 500,000, through the issuance of a maximum of 10,000,000 A Shares, with cancellation of the shareholders' preferential subscription rights in favor of a named person | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 | Carried | 26 171 469 | 99,55 | % | 118 145 | 0,45 | % | 26 740 | - | 26 289 614 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
3 |
Creation of a class of preferred shares referred to as "Class B preferred shares" convertible into ordinary shares (the "B Shares") - determination of the specific rights attached to the B Shares - corresponding amendment to the bylaws | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 | Carried | 26 189 117 | 99,63 | % | 97 794 | 0,37 | % | 29 443 | - | 26 286 911 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
4 |
Delegation of authority to the board of directors to increase the share capital by a maximum nominal amount of EUR 900,000, through the issuance of a maximum of 18,000,000 B Shares, with cancellation of the shareholders' preferential subscription rights in favor of a named person | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 | Carried | 26 198 396 | 99,63 | % | 96 411 | 0,37 | % | 21 547 | - | 26 294 807 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
5 | Cancellation of the shareholders' preferential subscription rights in favor of AstraZeneca Holdings B.V. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
5 | Carried | 26 205 300 | 99,67 | % | 88 077 | 0,33 | % | 22 977 | - | 26 293 377 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
6 |
Delegation of authority to the board of directors to carry out a share capital increase reserved for members of a company savings plan set up in accordance with Articles L. 3332-1 et seq. of the French Labor Code | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 | Rejected | 6 297 651 | 23,95 | % | 19 998 142 | 76,05 | % | 20 561 | - | 26 295 793 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % |
1/2
CELLECTIS Shareholders Meeting December 22, 2023
VOTING RESULTS
Ordinary Resolutions
NB | Resolution | Result | For | Against |
Vote withhold |
Total votes |
Shares represented by the votes cast |
Percentage of the share capital represented by the votes cast |
Out of vote voting rights |
Null voting rights | Quorum | ||||||||||||||||||||||||||||||||||||||||||||
Votes | % | Votes | % | Votes | % | ||||||||||||||||||||||||||||||||||||||||||||||||||
7 | Appointment of a director (Mr. Marc Dunoyer) subject to condition precedent | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
7 | Carried | 25 945 461 | 98,65 | % | 354 396 | 1,35 | % | 16 497 | - | 26 299 857 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % | ||||||||||||||||||||||||||||||||||||||
8 | Appointment of a director (Mr. Tyrell Rivers) subject to condition precedent | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
8 | Carried | 26 032 194 | 99,03 | % | 253 663 | 0,97 | % | 30 497 | - | 26 285 857 | 21 466 266 | 29,917 | % | 0 | 0 | 29,917 | % |
2/2
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cellectis SA published this content on 22 December 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 December 2023 21:04:22 UTC.